Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen’s Q2 Revenue Rises 13 Percent as Profit Doubles

NEW YORK (GenomeWeb News) — Invitrogen said Wednesday that its second-quarter revenue climbed 13 percent as R&D spending rose 11 percent and net income was up 108 percent.
 
Total receipts for the three months ended June 30, 2007 rose to $321.7 million from $285.4 million year over year.
 
Invitrogen’s Biodiscovery sales rose 10 percent to $223 million for the second quarter, while its Cell Culture Systems division saw revenue rise 20 percent to $99 million.
 
R&D spending increased to $28.6 million from $25.8 million year over year.
 
The company said net income grew to $40.9 million from $19.7 million in the year-ago period. This year's profit includes $11.5 million in income from discontinued operations compared with $678,000 for the same item in last year's second quarter.
 
Invitrogen said it had around $570.1 million in cash and equivalents and short-term investments as of June 30, 2006.
 
"The intense focus we placed on operations, IT infrastructure, and integrations during the last twelve months is delivering results," said Invitrogen CEO Greg Lucier.
 
The company said it expects full-year revenue growth for 2007 to be in the mid-single digits.
 
Also today, Invitrogen said it completed its 2006 $500 million share repurchase program, with the purchase of 0.7 million shares for $50 million within the quarter.
 
The company's board of directors has approved another, three-year $500 million share repurchase program.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.